2023-04-25 17:08:37 ET
- Finch Therapeutics ( NASDAQ: FNCH ) on Tuesday said it had appointed Matthew Blischak as CEO, effective May 16.
- The company said current CEO Mark Smith will conclude his role as top boss effective May 15.
- FNCH also announced the appointment of Lance Thibault as CFO.
- FNCH said Marc Blaustein will conclude his role as chief operating officer and as the company's principal financial officer, effective May 15.
- According to FNCH, Blischak has more than 20 years of intellectual property experience in the life sciences industry. He joins the company from Roivant Sciences ( ROIV ).
For further details see:
Finch Therapeutics brings on Roivant Sciences' Matthew Blischak as CEO